-
Endo Pharmaceuticals Inc., and Grunenthal GbmH v. Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. DC CAFC
- 1:12-cv-08060
- S.D.N.Y.
- Judge: J. Paul Oetken
+1
- Filed: 11/05/2012
- Closed: 06/29/2016
- Latest Docket Entry: 12/26/2023
- PACER
- Docket updated daily
2
Plaintiffs
3
Defendants
1
Accused
Product
6
Patents-in-Suit
1,333
Days in
Litigation
-
Endo Pharmaceuticals Inc., and Grunenthal GbmH v. Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. DC CAFC
- 1:12-cv-08060
- S.D.N.Y.
- Judge: J. Paul Oetken
+1
- Filed: 11/05/2012
- Closed: 06/29/2016
- Latest Docket Entry: 12/26/2023
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Referred Judge
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
-
Infringement
Barr Laboratories Incorporated
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg oxymorphone hydrochloride extended-release tabletGeneric 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg oxymorphone hydrochloride extended-release tablets | US 8,192,722 B2 | All Asserted Claims |
No infringement
Entry 215Entry 210 |
| Generic 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg Oxymorphone hydrochloride extended release tabletOxymorphone hydrochloride extended-release tablet | US 8,309,060 B2 | All Asserted Claims |
Infringement
Entry 225Entry 96 |
| 10 mg15 mg20 mg30 mg40 mg Oxymorphone hydrochloride extended release tablet5 mg7.5 mgGeneric 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg Oxymorphone hydrochloride extended release tabletOxymorphone hydrochloride extended-release tablet | US 8,309,122 B2 | All Asserted Claims |
Infringement
Entry 265Entry 225 Entry 96 |
| 10 mg15 mg20 mg30 mg40 mg Oxymorphone hydrochloride extended release tablet5 mg7.5 mgGeneric 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg Oxymorphone hydrochloride extended release tabletOxymorphone hydrochloride extended-release tablet | US 8,329,216 B2 | All Asserted Claims |
Infringement
Entry 265Entry 225 Entry 96 |
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg oxymorphone hydrochloride extended-release tablet | US 8,192,722 B2 | All Asserted Claims |
No infringement
Entry 210
|
Teva Pharmaceuticals USA, Inc.
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg oxymorphone hydrochloride extended-release tablet5mg, 7.5mg, 10mg, 15mg, 20mg, 30mg, 40mg oxymorphone hydrochloride extended-release tabletsGeneric 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg oxymorphone hydrochloride extended-release tablets | US 8,192,722 B2 | All Asserted Claims |
No infringement
Entry 215Entry 210 Entry 149 |
| Generic 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg Oxymorphone hydrochloride extended release tabletOxymorphone hydrochloride extended-release tablet | US 8,309,060 B2 | All Asserted Claims |
Infringement
Entry 225Entry 96 |
| 10 mg15 mg20 mg30 mg40 mg Oxymorphone hydrochloride extended release tablet5 mg7.5 mgGeneric 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg Oxymorphone hydrochloride extended release tabletOxymorphone hydrochloride extended-release tablet | US 8,309,122 B2 | All Asserted Claims |
Infringement
Entry 265Entry 225 Entry 96 |
| 10 mg15 mg20 mg30 mg40 mg Oxymorphone hydrochloride extended release tablet5 mg7.5 mgGeneric 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg Oxymorphone hydrochloride extended release tabletOxymorphone hydrochloride extended-release tablet | US 8,329,216 B2 | All Asserted Claims |
Infringement
Entry 265Entry 225 Entry 96 |
